Island Pharmaceuticals Limited
ASX: ILA.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Charles Foster
- Headquarters
- Camberwell, Australia
- IPO year
- 2021
- Market cap
- A$88.1M
- Website
- https://www.islandpharmaceuticals.com
Loading ILA…
Loading profile data…Frequently asked questions about ILA
What does Island Pharmaceuticals Limited (ILA.AX) do?
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with M...
Where does ILA.AX trade?
Island Pharmaceuticals Limited (ILA.AX) trades on the Australian Securities Exchange.
What sector is ILA.AX in?
Island Pharmaceuticals Limited (ILA.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Island Pharmaceuticals Limited?
David Charles Foster is the chief executive officer of Island Pharmaceuticals Limited (ILA.AX).
Where is Island Pharmaceuticals Limited headquartered?
Island Pharmaceuticals Limited is headquartered in Australia.
Does ILA.AX pay a dividend?
Island Pharmaceuticals Limited (ILA.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ILA.AX go public?
Island Pharmaceuticals Limited (ILA.AX) completed its initial public offering in 2021.